EA-2353 for the treatment of retinitis pigmentosa received fast track designation from the FDA, according to a press release from Endogena Therapeutics.
The gene-independent treatment approach activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors to possibly preserve or restore visual function, the release said.
A phase 1/2a dose-escalation study is underway to investigate the safety, tolerability and preliminary efficacy of EA-2353 administered intravitreally. Fourteen participants with retinitis pigmentosa are being recruited at six U.S. sites, with